World Wires · story 73819 · corroborated · 2 source(s)

Data confirms Moderna and Merck cancer vaccine meets trial endpoints

A clinical trial showed that a personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 42%.

Open in the desk

Coverage

• Moderna and Merck mRNA cancer vaccine reduces recurrence and death Hacker News front page · tier D · clear net · 2026-10-25 19:29 UTC
• Moderna and Merck shares fall despite cancer vaccine results NewsAPI headlines · tier B · clear net · 2026-10-22 22:24 UTC
• Data confirms Moderna and Merck cancer vaccine meets trial endpoints NewsAPI headlines · tier B · clear net · 2026-10-22 22:15 UTC

What this site indexes